Ubs Group Ag Aadi Bioscience, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AADI
# of Institutions
55Shares Held
12.6MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$8.52 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$5.98 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$5.53 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$5.52 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$2.29 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $62.8M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...